Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • COVID treatments

    - PMLiVE

    MHRA marks 100 years of patient safety through biological standards

    The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    University of Liverpool identifies new class of antibiotic in fight against AMR

    The new antibiotic class targets two of the WHO’s ‘priority pathogens’

    - PMLiVE

    Invivyd working with FDA towards potential Biologics License Application for COVID-19

    The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

    - PMLiVE

    FDA approves Pfizer and BioNTech’s jab for COVID-19

    Globally, five billion doses of the companies’ vaccine have been distributed

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    - PMLiVE

    EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive

    Kostaive is designed to instruct the body to make more mRNA to boost immune response

    - PMLiVE

    WHO urges US to ‘reconsider’ withdrawal from global health organisation

    President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

    - PMLiVE

    WHO launches $1.5bn emergency appeal to tackle ongoing health crises

    The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

    - PMLiVE

    Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

    The combined vaccine approach could simplify immunisation practices and lead to higher uptake

    - PMLiVE

    Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults

    Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19

    - PMLiVE

    Seven strategic steps to enhance patient recruitment & retention in your influenza studies

    The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

    Innovative Trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links